“Brown Financial Advisors Makes a New $1.71 Million Investment in Walmart Inc. (NYSE:WMT)”

Several hedge funds have modified their investments in Walmart (WMT). EntryPoint Capital gained a stake worth $25,000, while Northwest Capital’s position rose 199.3% to 440 shares valued at $26,000. TruNorth Capital increased its holdings by 138.3%, attaining 429 shares worth $29,000. Cultivar Capital and Able Wealth Management also initiated new stakes in WMT during Q2 and Q4, valued at $29,000 and $30,000, respectively. Institutional investors now control 26.76% of WMT shares.

Insider Activity

On August 1, EVP John D. Rainey sold 3,000 shares at $69.19, totaling $207,570, retaining 387,165 shares valued at $26.79 million. Major shareholder Alice L. Walton sold 2.71 million shares on September 3 at an average price of $77.37, worth approximately $209.61 million. In the past 90 days, insiders sold 12.33 million shares, holding 45.58% of the stock.

Analysts’ Forecasts

Piper Sandler upgraded its rating on WMT to �overweight� with a target of $83. Deutsche Bank and HSBC also raised their targets to $83 and $81, respectively. Overall, the consensus rating for Walmart is �Buy� with a target of $81.62.

Walmart’s Stock Performance

WMT opened at $81.27, with a 52-week range of $49.85 to $81.60. The company’s recent earnings report showed $0.67 EPS, surpassing estimates, with revenues of $169.30 billion, indicating a year-over-year increase of 4.7%. Analysts predict an EPS of 2.44 for the current year.

About Walmart

Walmart Inc. operates multiple retail segments globally, including Walmart U.S. and Sam’s Club, covering various store formats and eCommerce platforms.

Further Reading

• Five stocks we like better than Walmart
• Buffett’s Most Important Stock
• Lennar: A Housing Market Play
• Dividend Capture Strategy
• Energy Stocks Fueling AI Datacenter Boom
• Investing in Penny Stocks
• Marinus Pharmaceuticals in Biotech

Stay updated on hedge fund holdings in WMT at HoldingsChannel.com.